Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 5.50%
As of Thursday, October 15, Coya Therapeutics, Inc.’s COYA share price has surged by 5.50%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.
Commentary & Analysis
Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 5.05%
As of Tuesday, September 22, Coya Therapeutics, Inc.’s COYA share price has surged by 5.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 6.15%
As of Thursday, September 17, Coya Therapeutics, Inc.’s COYA share price has surged by 6.15%, which has investors questioning if this is right time to sell.Michael Rose
Why Coya Therapeutics, Inc.’s (COYA) Stock Is Up 6.28%
As of Monday, September 14, Coya Therapeutics, Inc.’s COYA share price has surged by 6.28%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About Coya Therapeutics, Inc.'s Q3 Earnings
Coya Therapeutics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (COYA) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | COYA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $97.1 | $228.7 | 22% |
|
| Shares Out (Mil) | 23.5 | 53.9 | 33% |
|
| Institutional Ownership | 80.8% | 92.9% | 49% |
|
| Float (Mil) | 17.5 | 42.1 | 27% |
|
| Beta | 0.62 | 0.95 | 36% |
|
| Avg Daily Volume (000s) | 152 | 574 | 41% |
|
| Price Change (52-week) |
(35.4%) | 47.3% | 27% |
|
| Growth | COYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (97.8%) | (10.1%) | 2% |
|
| EPS (5yr) | (16.2%) | 15.8% | 17 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (41.1%) | (15.7%) | 11% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.353) | ($1.367) | ($1.920) | |
| Month Ago EPS | ($0.353) | ($1.367) | ($1.880) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.390) | ($1.475) | ($1.827) | |
| Year/Year Chg | 24.7% | 7.7% | (15.3%) | |
| Financials | COYA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $37 | 8% |
|
| Net Income (TTM) (Mil) | ($22) | ($44) | 23% |
|
| EPS (TTM) | ($1.089) | ($1.500) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($33) | 17% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $2 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $60 | $177 | 17% |
|
| Valuation | COYA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.25 | 2.24 | 58% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | COYA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (111.8%) | 66.9% | 2% |
|
| Net Margin | (270.2%) | (73.7%) | 3% |
|
| ROA | (53.7%) | (47.0%) | 11% |
|
| ROE | (60.5%) | (54.1%) | 13% |
|
| Liabilities to Assets | 8.5% | 29.1% | 5% |
|
| F-Score | 3 | 2 | 18% |
|
Coya Therapeutics, Inc. did not pass any screens on 10/21/2026.
